<DOC>
	<DOCNO>NCT00661193</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving erlotinib together carboplatin paclitaxel may kill tumor cell . PURPOSE : This randomized phase II trial study well erlotinib work give alone together carboplatin paclitaxel treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>S0709 : Erlotinib With Without Carboplatin Paclitaxel Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To select regimen ( erlotinib hydrochloride without carboplatin paclitaxel ) test standard treatment , base median progression-free survival ≥ 3 month , patient stage IIIB IV non-small cell lung cancer Zubrod performance status 2 . Secondary - To assess feasibility select patient trial base central EGFR test serum cooperative group set . - To evaluate objective tumor response rate ( confirm unconfirmed , complete partial response ) , subset patient measurable disease . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral erlotinib hydrochloride daily day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . - Arm II : Patients receive paclitaxel IV 3 hour carboplatin IV 30 minute day 1 oral erlotinib hydrochloride daily day 2-16 . Treatment repeat every 21 day 4 course . Beginning course 5 subsequent course , patient receive oral erlotinib hydrochloride alone day 1-21 . Courses erlotinib hydrochloride repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year every 6 month 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) , include follow subtypes : Adenocarcinoma Large cell carcinoma Squamous cell carcinoma Unspecified Newly diagnose primary disease OR recurrent disease prior surgery and/or radiotherapy , meet 1 follow stag criterion : Selected stage IIIB disease ( T4 [ secondary malignant pleural effusion ] , N , M0 ) Stage IV disease ( T , N , M1 [ distant metastasis present ] ) Measurable nonmeasurable disease CT scan , MRI , xray , physical exam , nuclear scan The CT scan combine PET/CT scan may use document nonmeasurable disease Pleural effusion , ascites , laboratory parameter acceptable evidence disease Shows evidence EGFR tyrosine kinase inhibitor therapy benefit ( i.e. , `` proteomics positive '' ) prior study registration No untreated brain metastasis Patients treat brain metastasis allow provided metastasis remain control least two week follow treatment , AND patient residual neurological dysfunction corticosteroid Patients neurologic abnormality physical examination symptom must negative pretreatment CT MRI scan brain 28 day prior registration PATIENT CHARACTERISTICS : Zubrod performance status 2 ANC ≥ 1,500/mm³ Platelet count ≥ 1,000/mm³ Serum bilirubin normal SGOT SGPT normal Serum creatinine ≤ 2 time upper limit normal OR creatinine clearance ≥ 50 mL/min Willing provide prior smoke history request prestudy form No gastrointestinal ( GI ) tract disease result inability take enteral medication No malabsorption syndrome requirement IV alimentation No uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease ulcerative colitis ) No significant history cardiac disease , include follow : Uncontrolled high blood pressure Unstable angina Congestive heart failure Myocardial infarction within past 6 month Cardiac ventricular arrhythmia require medication No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer patient currently complete remission , cancer patient diseasefree 5 year Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 week since prior radiotherapy surgery ( thoracic major surgery ) recover At least 1 year since prior adjuvant chemotherapy No prior systemic hormonal therapy , chemotherapy , biological therapy advance NSCLC No prior EGFR inhibitor No prior surgical procedure affect absorption No concurrent major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>